Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.69 |
| ▸ | DRD2 | P14416 | 2/20 | 0.69 |
| ▸ | DRD3 | P35462 | 2/20 | 0.69 |
| ▸ | HTR1A | P08908 | 9/20 | 0.64 |
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | DRD4 | P21917 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | HTR7 | P34969 | 2/20 | 0.60 |
| ▸ | HTR3A | P46098 | 8/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30839792 | 1.00 | ADRB1 (0.69) | ADRB1DRD2DRD3HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL30183272 | 0.98 | ADRB1 (0.67) | ADRB1DRD2DRD3HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL5373698 | 0.98 | ADRB1 (0.67) | ADRB1DRD2DRD3HTR1AHTR2A | |
| SCHEMBL24388809 | 0.83 | DRD2 (0.50) | ADRB1DRD2DRD3HTR1AHTR2A | |
| SCHEMBL29367982 | 0.81 | DRD2 (1.00) | ADRB1DRD2DRD3HTR1AHTR2A | |
| SCHEMBL218837 | 0.81 | ADRB1 (1.00) | ADRB1DRD2DRD3HTR1AHTR2A | |
| SCHEMBL18829750 | 0.81 | GAA (0.50) | ADRB1DRD2DRD3HTR1AHTR2A | |
| SCHEMBL8511 | 0.81 | DRD2 (1.00) | ADRB1DRD2DRD3HTR1AHTR2A | |
| SCHEMBL29699369 | 0.81 | ADRB1 (1.00) | ADRB1DRD2DRD3HTR1AHTR2A | |
| SCHEMBL6352699 | 0.81 | DRD2 (1.00) | ADRB1DRD2DRD3HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368115-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHUJING BIOPHARMA CO., LTD (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4382521-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shujing Biopharma Co., Ltd (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-112778183-B | Nitrogen-containing ring derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117769545-A | Tri-fused ring derivative-containing regulator, preparation method and application thereof | 上海枢境生物科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023011608-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海枢境生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| WO-2023011608-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海枢境生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3886845-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2, 3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-112778183-A | Nitrogen-containing ring derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-05-11 | — | — | CN | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
| US-6121267-A | ADMINISTERING DOPAMINE ANTAGONIST TO TREAT PSYCHOLOGICAL DISORDER, I.E., SCHIZOPHRENIA | WARNER-LAMBERT COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| US-5965560-A | AS DOPAMINE ANTAGONISTS AND ANTIPSYCHOTIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1997041108-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS CENTRAL NERVOUS SYSTEM AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-11-06 | — | — | WO | disclosed |
| EP-0367141-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1996-01-10 | — | — | EP | disclosed |
| US-5006528-A | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-09 | — | — | US | disclosed |
| EP-0367141-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368115-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TPH1, TPH2, GAP43 | ADRB1 10/4885DRD2 327/4885DRD3 801/4885 |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | ADRB1 371/4885DRD2 2/4885DRD3 3/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | ADRB1 371/4885DRD2 2/4885DRD3 3/4885 |
| US-20230008022-A1 | NOVEL SUBSTITUTED PIPERAZINE AMIDE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | ADRB1 3264/4885DRD2 3134/4885DRD3 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.